Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[89Zr]Zr-DFO-EGFRvIII is a preclinical-stage antibody-based radiopharmaceutical designed for immuno-positron emission tomography (immunoPET) imaging of glioblastoma (GBM). It consists of a monoclonal antibody targeting the epidermal growth factor receptor variant III (EGFRvIII) mutation, conjugated with the chelator deferoxamine (DFO) and radiolabeled with the positron-emitting isotope zirconium-89 (89Zr). Developed by researchers at the University of Santiago de Compostela and the Vall d'Hebron Institute of Oncology, this tracer is used to non-invasively assess and quantitatively map EGFRvIII expression in vivo, particularly in glioblastoma models, to aid in patient stratification for EGFRvIII-targeted therapies.
| Indication | Highest phase | Status |
|---|---|---|
| glioblastoma, IDH-wildtype | Preclinical | Active |
Every indication, with countries and timelines, is in the full profile.
| Market | Status | Year |
|---|---|---|
| United States | Not approved | — |
| European Union | Not approved | — |
| China | Not approved | — |
| Japan | Not approved | — |
Approved indications and other markets are in the full profile.
Lead indication: glioblastoma, IDH-wildtype
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [89Zr]Zr-DFO-EGFRvIII.
Work on [89Zr]Zr-DFO-EGFRvIII? Claim this page to correct or add information. Claim this page